8V9F
 
 | | BRD4 BD1 liganded with macrocyclic compound 2d (JJ-II-363A) | | Descriptor: | (4bS)-1-ethyl-7,20-dimethyl-4b,10,11,21-tetrahydro-2H,17H-dibenzo[12',13':5',6'][1,4,8]trioxacyclotridecino[11',10':4,5]pyrido[2,3-d]pyrimidine-2,4,19(1H,3H)-trione, 1,2-ETHANEDIOL, Bromodomain-containing protein 4 | | Authors: | Schonbrunn, E, Chan, A. | | Deposit date: | 2023-12-08 | | Release date: | 2024-12-18 | | Last modified: | 2025-05-28 | | Method: | X-RAY DIFFRACTION (1.22 Å) | | Cite: | Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors.
Eur.J.Med.Chem., 290, 2025
|
|
8V92
 | | BRD4 BD1 liganded with macrocyclic compound 2b (JJ-II-352A) | | Descriptor: | (4bS)-1-ethyl-21-methyl-4b,11,12,22-tetrahydro-2H,10H,18H-dibenzo[13',14':6',7'][1,5,9]trioxacyclotetradecino[12',11':4,5]pyrido[2,3-d]pyrimidine-2,4,20(1H,3H)-trione, 1,2-ETHANEDIOL, Bromodomain-containing protein 4 | | Authors: | Schonbrunn, E, Chan, A. | | Deposit date: | 2023-12-07 | | Release date: | 2025-03-19 | | Last modified: | 2025-04-02 | | Method: | X-RAY DIFFRACTION (1.27 Å) | | Cite: | Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors.
Eur.J.Med.Chem., 290, 2025
|
|
